Stryker Corp

• Thermo Fisher shares rose following positive management commentary at the healthcare conference. • Executive leadership highlighted recovering client spending in biopharma and life sciences. • The company reported $44.56B in annual revenue and $6.70B in net profit.

• RBC Capital Markets upgraded ResMed to Outperform, raising its price target. • ResMed launched an accelerated share repurchase program funded by MatrixCare divestiture proceeds. • Strong global device revenue and competitor regulatory disruptions supported market share momentum.

• HCA Healthcare reported strong operational performance and profit growth tracking near historical targets. • Management updates eased market concerns regarding policy-related payer mix and inflation pressures. • The stock features a neutral MACD, an RSI of 57.712, and a buy signal.

• UnitedHealth experienced price volatility after management discussed persistent medical utilization trends and costs. • Institutional investors took profits following a multi-month stock advance and elevated expectations. • Technical indicators show neutral MACD and RSI values alongside an oversold Williams %R.

• Intuitive Surgical faced selling pressure from moderated domestic elective procedure growth. • Rising competition from rival medical robotic systems created investor sentiment drag. • Premium valuation multiples and insider stock sales compounded recent downside momentum.

• ResMed faced selling pressure due to Astral ventilator suspension expenses and margin pressures. • Sector sentiment remains constrained by GLP-1 concerns and potential Philips market re-entry. • ResMed completed the MatrixCare divestiture, funding accelerated share repurchases and increased dividends.